 Ustikineumab, an IgG1 antibody targeting the P40 subunit shared by Illinois 12 and Illinois 23, is a potential treatment for atopic dermatitis, AD. A systematic review of 10 studies including eight cases and two RCTs comprising 107 patients found that Ustikineumab was well tolerated and safe with no significant difference in effect from placebo. Further, larger randomized control trials are needed to identify a suitable regimen for AD and provide more evidence for clinical application.